Limits of serum carcinoembryonic antigen and carbohydrate antigen 19-9 as the diagnosis of gallbladder cancer

Jae Seung Kang, Su Young Hong, Youngmin Han, Hee Ju Sohn, Mirang Lee, Yoon Hyung Kang, Hyeong Seok Kim, Hongbeom Kim, Wooil Kwon, Jin-Young Jang

Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

INTRODUCTION

Gallbladder cancer (GBC) is the most common malignant disease in the biliary tract, accounting for 80%–95% of biliary tract cancer (BTC) [1]. Although the only curative treatment of GBC is complete surgical resection, only 10% of patients are candidates for the surgery at diagnosis because most GBC are found in locally advanced or metastatic status [2]. Therefore, it is important to detect GBC at an early stage, thereby allowing for the performance of curative-intent surgical resection and better survival outcomes. However, the detection of GBC at an earlier stage is still challenging because the clinical symptoms are lacking or vague, or many symptoms manifest in advanced GBC [3].

Tumor biomarkers are often investigated to diagnose malignant disease and to detect disease progression or recurrence [4]. Many studies have already revealed the clinical

Purpose: Although serum CEA and CA 19-9 have been widely utilized for the diagnosis of gallbladder cancer (GBC), few studies have examined the diagnostic performance of them. This study aimed to investigate the diagnostic performance of these 2 biomarkers and demonstrate their clinical usefulness in diagnosing GBC.

Methods: Between January 2000 and March 2020, a total of 751 GBC patients and 2,310 normal controls were included. Serum CEA and CA 19-9 were measured preoperatively. Receiver operating characteristic curves were obtained, and the sensitivity and specificity of each biomarker were evaluated.

Results: In terms of differentiating GBC from the control, the sensitivity and specificity of serum CEA at 5 ng/mL was 12.1% and 99.1%, respectively, and those of serum CA 19-9 at 37 IU/mL were 28.7% and 94.5%, respectively. The optimal cutoff values of CEA and CA 19-9 were set to 2.1 ng/mL and 26 IU/mL in the receiver operating characteristic curves, respectively. The sensitivities of CEA and CA 19-9 at new cutoff values slightly increased but remained low (CEA, 42.9%; CA 19-9, 38.2%).

When differentiating early-stage GBC from advanced tumor, the sensitivity and specificity, were 14.2% and 96.1% for CEA (cutoff value, 5 ng/mL) and 33.6% and 90.1% for CA 19-9 (cutoff value, 37 IU/mL), respectively.

Conclusion: Serum CEA and CA 19-9 levels are not suitable for screening GBC patients from controls. New promising biomarkers with higher sensitivity should be explored.

Key Words: Biomarkers, Diagnosis, Gallbladder, Sensitivity and specificity
usefulness of CEA and CA 19-9 in terms of pancreatic cancer [5]. These 2 biomarkers have been utilized in BTC, and some previous studies have evaluated the clinical usefulness of these 2 biomarkers for the diagnosis of BTC with sensitivity of 50%–70% and specificity of 50%–85% [6,7]. However, these studies were small-scale, and not specific for GBC. Therefore, the current study aimed to investigate the diagnostic performance of serum CEA and CA 19-9 levels in large-scaled cohorts and to demonstrate the clinical implications of these 2 biomarkers in terms of GBC.

METHODS

Patients
This was a retrospective cohort study utilizing a prospectively collected medical database. Between January 2000 and March 2020, patients who underwent surgical resection had pathologically proven GBC were included in the cancer group. The control group included patients who underwent cholecystectomy for benign gallbladder diseases such as asymptomatic gallbladder stone, gallbladder fundal adenomyomatosis, benign gallbladder polyp, or acute cholecystitis between January 2000 and December 2015. Patients who underwent neoadjuvant chemotherapy or radiotherapy were excluded. Patients who did not have detailed pathologic and laboratory findings were excluded. All patients underwent preoperative pancreatobiliary protocol CT to investigate the tumor extent, regional lymph node (LN) enlargement, distant metastasis, and detection of other suspicious malignancies.

This study was approved by the Institutional Review Board of Seoul National University Hospital (No. 1812-002-989) and informed consent was obtained.

The classification of early GBC
Tumor-node-metastasis stages were unified with the 7th edition of the American Joint Committee on Cancer (AJCC) stage for GBC. Early GBC was classified as a Tis or T1 tumor without regional LN metastasis or distant metastasis. T1 GBC patients who did not need to undergo lymphadenectomy because of no suspicious LN metastases in the preoperative CT image were considered early GBC patients.

Quantitative measurement of serum CEA and CA 19-9 level
All patients included in this study had serum CEA and CA 19-9 levels measured within 2 weeks before surgery. Serum CEA levels were measured using immunoradiometric assay (IRMA) kits, a 1-step noncompetitive sandwich method (Shin Jin Medics, Ilsan, Korea). Serum CA 19-9 concentrations were measured using CA 19-9 [125I] IRMA kits based on the use of the 1116NS19-9 antibody (Institute of Isotopes [IZOTOP], Budapest, Hungary).

Statistical analysis
Serum CEA and CA 19-9 levels were described as medians along with interquartile ranges (IQRs, i.e., first-third quartiles).

Table 1. Clinicopathologic findings of the gallbladder cancer and the control group

| Variable                        | Cancer group | Control group | P-value |
|---------------------------------|--------------|---------------|---------|
| No. of patients                 | 751          | 2,310         |         |
| Age (yr)                        | 65.6 ± 10.3  | 54.3 ± 13.9   | <0.001  |
| Sex, male:female                | 356 (47.4):395(52.6) | 1,088(47.1):1,222(52.9) | 0.868   |
| Body mass index (kg/m$^2$)      | 23.9 ± 3.2   | 24.3 ± 3.4    | 0.017   |
| CEA (IU/mL)                     | 1.9 (1.2–3.1)| 1.4 (1.0–2.0) | <0.001  |
| CA 19-9 (IU/mL)                 | 16 (6–46)    | 7.5 (2.8–15.6)| <0.001  |

Values are presented as number only, mean ± standard deviation, number (%), or median (interquartile range).
Due to the skewed distribution of serum CEA and CA 19-9 levels, log-transformation was performed and comparisons between tumor markers and categorical variables (GBC vs. normal control, early vs. advanced GBC) were performed using Student t-test or Mann-Whitney U-test, as appropriate. Receiver operating characteristic (ROC) curves were obtained to determine the optimal cutoff values of serum CEA and CA 19-9 levels and to evaluate the sensitivity and specificity of these 2 biomarkers.

RESULTS

Clinicopathologic findings between the gallbladder cancer group and the control group

A total of 751 and 2,310 patients were included in the GBC group and the control group, respectively (Table 1). Median CEA was 1.9 ng/mL (IQR, 1.2–3.1 ng/mL) and 1.4 ng/mL (IQR, 1.0–2.0 ng/mL) in the GBC group and the control group, respectively. Median CA 19-9 was 16 IU/mL (IQR, 6–46 IU/mL) and 7.5 IU/mL (IQR, 2.8–15.6 IU/mL) in the GBC group and the control group, respectively. In the GBC group, 636 patients (84.7%) were pathologically diagnosed with adenocarcinoma, followed by 54 with intracholecystic papillary neoplasm (7.2%), and 16 with adenosquamous carcinoma (2.1%). 55 patients (7.4%) were in stage 0, 117 patients (15.6%) were in stage I, 255 patients (34.0%) were in stage II, 227 patients (30.2%) were in stage III, and 117 patients (15.6%) were in stage IV. Of the control group, 1,787 patients (77.4%) underwent surgery for gallbladder stones, 269 patients (11.6%) for benign polyps, and 112 patients (4.8%) for cholecystitis.

Performance of serum CEA and CA 19-9 levels with regard to the diagnosis of gallbladder cancer

A total of 660 patients (87.9%) had a serum CEA level of 5 ng/mL or less and 535 patients (71.2%) had a serum CA 19-9 level of 37 IU/mL or less (Table 2). Fig. 1 shows the distribution of log-transformed serum CEA levels (Fig. 1A) and log-transformed serum CA 19-9 levels (Fig. 1B); the levels of both these biomarkers were higher in the GBC group than in the control group. However, when classified with the AJCC 7th stage, the overall distributions of log-transformed serum CA 19-9 levels were comparable among the control, stage 0, I, and II GBC groups (Fig. 2) and the median serum CA 19-9 levels were 75 IU/mL for control, 13.4 IU/mL for stage 0, 10.7 IU/mL for stage I, and 11 IU/mL for stage II cancer patients. Patients in stages III and IV showed a higher distribution of serum CA 19-9 levels than the stage I and II groups (median, 34 IU/mL vs. 11 IU/mL; Supplementary Fig. 1A), and the group with distant metastasis showed higher serum CA 19-9 levels than those without metastasis (median, 80 IU/mL vs. 15 IU/mL; Supplementary Fig. 1B).

Diagnostic performance of serum CEA and CA 19-9 level for diagnosing gallbladder cancer

When the cutoff values of serum CEA and CA 19-9 levels were set to 5 ng/mL and 37 IU/mL for differentiating GBC from the normal control, the sensitivity and specificity of CEA were 12.1% and 99.1%, respectively, and those of CA 19-9 were 28.7%
and 94.5%, respectively (Table 3). When the same cutoff value was applied to differentiate early GBC (stage 0 and I) from the normal control, the sensitivity and specificity of CEA were 22.2% and 94.0%, respectively, and those of CA 19-9 were 10.6% and 94.1%, respectively.

And then, the diagnostic performance of the composition of CEA and CA 19-9 were evaluated (Table 4). In regards to the diagnosis of all stage GBC, the sensitivity became higher than that of each biomarker, although the positive predictive value became lower. The sensitivity of diagnosis of early GBC remained less than 30%.

### Diagnostic performance of serum CEA and CA 19-9 levels for differentiating gallbladder cancer stage

When the cutoff value was set to 5 ng/mL of serum CEA and 37 IU/mL of serum CA 19-9 for differentiating early GBC from advanced tumors, the sensitivity and specificity of CEA were 14.2% and 96.1%, respectively, and those of CA 19-9 were 11.6% and 94.6%, respectively (Table 3). When the same cutoff values were applied to differentiate stage 0, I, and II cancer from stage III and IV cancer, the sensitivity and specificity of CEA were 18.9% and 93.6%, respectively; and those of CA 19-9 were 46.8% and 86.5%, respectively.

### Table 3. Diagnostic performance of tumor markers according to the cutoff value and cancer stage

| Variable                        | Tumor marker | Cutoff value | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) |
|---------------------------------|--------------|--------------|----------------|----------------|---------|---------|--------------|
| **Control vs. cancer**          | CEA          | 5 ng/mL      | 12.1           | 99.1           | 81.3    | 77.6    | 77.8         |
|                                  |              | 2.1 ng/mL    | 42.9           | 81.3           | 42.8    | 81.4    | 71.9         |
|                                  | CA 19-9      | 37 IU/mL     | 28.7           | 94.5           | 63.0    | 80.3    | 78.4         |
|                                  |              | 26 IU/mL     | 38.2           | 89.0           | 53.1    | 81.6    | 76.5         |
| **Control vs. stage 0, I cancer**| CEA          | 5 ng/mL      | 22.2           | 94.0           | 4.0     | 99.1    | 93.2         |
|                                  |              | 2.1 ng/mL    | 28.3           | 81.3           | 9.1     | 94.5    | 78.1         |
|                                  | CA 19-9      | 37 IU/mL     | 10.6           | 94.1           | 9.9     | 94.5    | 89.3         |
|                                  |              | 26 IU/mL     | 15.8           | 89.1           | 8.7     | 94.1    | 84.5         |
| **Stage 0, I cancer vs. stage II, III, IV cancer** | CEA          | 5 ng/mL      | 14.2           | 96.1           | 93.4    | 22.1    | 30.8         |
|                                  |              | 2.1 ng/mL    | 45.9           | 71.7           | 86.5    | 25.2    | 51.1         |
|                                  | CA 19-9      | 37 IU/mL     | 33.6           | 90.1           | 93.1    | 25.6    | 45.0         |
|                                  |              | 26 IU/mL     | 42.4           | 84.2           | 91.4    | 27.1    | 50.8         |
| **Stage 0, I, II cancer vs. stage III, IV cancer** | CEA          | 5 ng/mL      | 18.9           | 93.6           | 71.4    | 57.7    | 59.4         |
|                                  |              | 2.1 ng/mL    | 50.3           | 64.4           | 54.4    | 60.5    | 57.9         |
|                                  | CA 19-9      | 37 IU/mL     | 46.8           | 86.5           | 74.5    | 65.8    | 68.3         |
|                                  |              | 26 IU/mL     | 55.2           | 78.4           | 68.4    | 67.4    | 67.8         |

PPV, positive predictive value; NPV negative predictive value.

### Table 4. Diagnostic performance of the composition of carcinoembryonic antigen and carbohydrate antigen for diagnosing gallbladder cancer and early-stage gallbladder cancer

| Variable                        | Tumor marker | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) |
|---------------------------------|--------------|----------------|----------------|---------|---------|--------------|
| **Control vs. cancer**          | CEA (>5) or CA 19-9 (>37) | 33.8 | 93.9 | 64.1 | 81.4 | 79.1 |
|                                  | CEA (>5) and CA 19-9 (>37) | 7.1 | 99.7 | 89.8 | 76.8 | 77.0 |
| **Control vs. stage 0, I cancer**| CEA (>5) or CA 19-9 (>37) | 12.5 | 93.9 | 11.8 | 94.2 | 88.8 |
|                                  | CEA (>5) and CA 19-9 (>37) | 1.3 | 99.7 | 25.0 | 93.9 | 93.7 |

CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; PPV, positive predictive value; NPV, negative predictive value.
Annals of Surgical Treatment and Research 2021;101(5):266-273

Setting of optimal cutoff values of serum CEA and CA 19-9 levels via receiver operating characteristic curve analysis

Fig. 3 shows the ROC curves of serum CEA levels and serum CA 19-9 levels for the diagnosis of GBC. Overall, the optimal cutoff value for differentiating GBC from the controls was 2.1 ng/mL of CEA (Fig. 3A) and 26 IU/mL of CA 19-9 (Fig. 3B), and the sensitivity and specificity at these cutoff values were 42.9% and 81.3%, respectively, for serum CEA and 38.2% and 89.0%, respectively, for serum CA 19-9 (Table 3). When diagnosing early GBC (stage 0 and I) from the control group, the sensitivities of serum CEA and CA 19-9 at these cutoff values were 28.3% and 15.8%, respectively. The sensitivity of serum CEA and CA 19-9 for differentiating stage 0, I, and II cancer from stage III and IV cancer was higher when the cutoff values for CEA and CA 19-9 were changed from 5.0 to 2.1 ng/mL and from 37 to 26 IU/mL, respectively.

DISCUSSION

Since GBC manifests as vague or with no symptoms, it cannot be diagnosed by clinical symptoms alone and objective and noninvasive tools are necessary to accurately diagnose GBC. Therefore, novel diagnostic biomarkers with high sensitivity that can detect the disease in a screening population without symptoms [8], and can detect the disease specifically and noninvasively are needed [9]. Many tumor biomarkers have been utilized to detect malignant disease: for example, CA 125 for ovarian cancer [10], or prothrombin in vitamin K absence-II and alpha-fetoprotein for hepatocellular carcinoma [11]. Although some biomarkers, such as cytokeratin 19 fragments, matrix metalloproteinase-7, or osteopontin were proposed as potential diagnostic biomarkers for BTC, these biomarkers were investigated with small-scaled studies, and were only utilized in limited situations [12-15]. Although serum CA 19-9 and CEA levels have been considered as diagnostic biomarkers for BTC, their diagnostic performance for BTC remains controversial. Some previous studies have investigated the diagnostic performance of serum CA 19-9 and CEA in terms of BTC, but they were small-scale and not specific to GBC [16]. Although the incidence of BTC is relatively high in Chile, South America, India, and Eastern Asia, few studies on BTC can be found in these countries [17]. This study evaluated the diagnostic performance of these 2 biomarkers with a large number of GBC patients and a control group in a high-incidence country and demonstrated their clinical usefulness as a screening program for GBC.

Age, body mass index (BMI), or sex could affect preoperative CEA and CA 19-9 level. Therefore, the propensity score matching analysis was performed and the ranges of preoperative CEA and CA 19-9 level were compared before and after propensity score matching. Because age (65.3 years vs. 54.3 years, P < 0.001) and BMI (23.9 kg/m² vs. 24.3 kg/m², P = 0.017) were significantly different between the GBC and normal control group, the propensity score matching with age and sex was performed and the median and IQR of CEA and CA 19-9 were similar before and after propensity score matching. Therefore, age, sex, and BMI might not affect the preoperative serum CEA and CA 19-9 level. Finally, we analyzed all the data collected.

Conventionally, the cutoff value for determining benign and malignant disease at diagnosis is 5 ng/mL of serum CEA and 37 IU/mL of serum CA 19-9. However, these cutoff values were based on the results from colorectal cancer (CEA, 5 ng/mL) and pancreatic cancer (CA 19-9, 37 IU/mL) [18], and no studies existed in regards to the GBC. In the present study, 87.9% of GBC patients had CEA levels of ≤5 ng/mL and 71.2% of patients had CA 19-9 levels of ≤37 IU/mL (Table 2). Most patients with GBC had these 2 biomarkers within the conventional cutoff values.
Therefore these cutoff values were not suitable for diagnosing GBC and new criteria would be needed to screen for GBC.

CA 19-9 is a tumor-associated antigen, initially isolated as a colorectal cancer antigen, but also presented in epithelial cells of the gallbladder, biliary tract, pancreas, and stomach [19]. Serum CA 19-9 level is elevated in patients with not only malignant disease, but also liver cirrhosis, jaundice, or inflammatory conditions [19,20]. In contrast, serum CA 19-9 was undetectable in some patients with Lewis-antigen negative phenotype [21]. The median sensitivity of CA 19-9 for the diagnosis of pancreatic cancer was reported as 79% [22]. However, in the present study, the sensitivity of CA 19-9 for the diagnosis of GBC did not exceed 30% at the conventional cutoff values (37 IU/mL) (Table 3). Therefore, the 37 IU/mL is not a reliable cutoff value of serum CA 19-9 for the diagnosis of GBC without reliable sensitivity as the screening test.

CEA is a glycoprotein involved in cell adhesion and is normally produced during fetal development; however, its production stops before birth [23]. While serum CEA is elevated in patients with colorectal cancer, it can also be elevated in smokers, and in cases of ulcerative colitis, liver cirrhosis, and chronic bronchitis [24]. The sensitivity of CEA for diagnosis was reported to be low, with a sensitivity of 50% in pancreatic cancer [25], and 33% in BTC [6]. In this study, the sensitivity of CEA was 12.1% for diagnosing GBC and 22.2% for diagnosing early GBC when the cutoff value was 5 ng/mL (Table 3). Current cutoff values of CEA and CA 19-9 are not suitable for the diagnosis of entire GBC and that of early-stage GBC. Therefore, new cutoff values suitable for the diagnosis of GBC are needed. In this study, the ROC curves of serum CEA and CA 19-9 levels were evaluated using the database of 751 GBC patients and 2,310 normal controls (Fig. 3A). The optimal cutoff value of CEA was set to 2.1 ng/mL (Fig. 3A) and that of CA 19-9 was set to 26 IU/mL (Fig. 3B). The sensitivity of the proposed cutoff value was higher than that with the previous cutoff value that the sensitivity of CEA and CA 19-9 for the diagnosis of GBC rose to about 40% (Table 3). However, a sensitivity of 40% is not sufficient for a novel diagnostic tool. Furthermore, the sensitivity of CEA and CA 19-9 did not exceed 30% when these biomarkers were utilized to diagnose early GBC, and that of the composition of 2 biomarkers remained less than 30%. Therefore, these 2 biomarkers would not be suitable for detecting early GBC.

In regards to the disease severity, the sensitivity of the 2 biomarkers exceeded 50% when they were utilized to differentiate stage III and IV cancers from stage 0, I, and II cancers. Furthermore, the stage III and IV groups showed a higher distribution of serum CA 19-9 levels than did the stage I and II groups (median, 34 IU/mL vs. 11 IU/mL; Supplementary Fig. 1A). Considering that both biomarkers had high specificity for diagnosis and reliable sensitivity for differentiating cancer stage, these 2 biomarkers would be useful for the evaluation of disease severity, but not as a screening tool.

Radiologic modalities are the gold standard tools for diagnosing GBC. Ultrasonography is widely utilized for screening due to its noninvasiveness and real-time evaluation. Although ultrasonography has good performance for diagnosing gallbladder polyps, it is still difficult to differentiate neoplastic polyps from non-neoplastic polyps [26]. In particular, the sensitivity of CT images was reported to be 54% when the gallbladder lesion was T1 with only a thickened wall [27]. Because the ultrasonography results depend on the practitioner, new diagnostic biomarkers with higher sensitivity and objectivity should be included in the screening programs for GBC. If GBC can be diagnosed at an early stage, minimally invasive surgery such as laparoscopic or robotic cholecystectomy can be the appropriate treatment with comparable perioperative outcomes [28].

Although this study had some limitations related to a retrospective cohort study, this study evaluated more than 700 surgically resected GBC patients and over 2,000 normal controls. Considering that most previous studies on GBC analyzed a small number of patients in Western countries, this study was conducted in the Republic of Korea, in which the prevalence of GBC is much higher than that in other Western countries [29]. One study reported a high incidence of specific genomic mutations in Korea, which was not frequently found in other Western countries [30]. Therefore, if these researchers investigate new biomarkers for GBC, they should consider the difference in prevalence related to geographic variation.

In conclusion, serum CEA and CA 19-9 had low sensitivity and high specificity for diagnosing GBC, especially for the early GBC, thereby making them unsuitable for screening GBC patients from the normal control group. New biomarkers with high sensitivity for the diagnosis of GBC should be explored.

SUPPLEMENTARY MATERIALS

Supplementary Fig. 1 can be found via https://doi.org/10.4174/astr.2021.101.5.266.

ACKNOWLEDGEMENTS

Fund/Grant Support
This research was supported by the Collaborative Genome Program for Fostering New Post-Genome Industry of the National Research Foundation funded by the Ministry of Science and ICT in Republic of Korea (NRF-2017M3C9A5031591).

Conflict of Interest
No potential conflict of interest relevant to this article was reported.
REFERENCES

1. Rakić M, Patrilj L, Koplar M, Klíček R, Kolovrat M, Loncar B, et al. Gallbladder cancer. Hepatobiliary Surg Nutr 2014;3:221-6.
2. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist 2010;15:168-81.
3. Kumar S, Bhorival S, Muduly D, Kar M, Sharma A, Pathy S, et al. Multimodality management of incidentally detected gall bladder cancer: long term results from a tertiary care cancer centre. J Gastrointest Oncol 2019;10:128-33.
4. Mamdani H, Ahmed S, Armstrong S, Mok T, Jalal SI. Blood-based tumor biomarkers in lung cancer for detection and treatment. Transl Lung Cancer Res 2017;6:648-60.
5. Kau SY, Shyr YM, Su CH, Wu CW, Lui WY. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. J Am Coll Surg 1999;188:415-20.
6. Björnsson E, Kilander A, Olsson R. CA 19-9 and CEA in periampullary cancers. J Surg Oncol 1991;48:37-40.
7. Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci 2011;56:2491-6.
8. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012;3:105-19.
9. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thormaugh M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
10. Muinao T, Deka Boruah HP, Pal M. Multibiomarker panel signature as the key to diagnosis of ovarian cancer. Hellyon 2019;5:e02826.
11. Park SJ, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, et al. Usefulness of AFP, AFP-L3, CA 19-9 and CEA in the differential diagnosis of cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol 2009;9:30.
12. Chapman MH, Sandanayake NS, Andreola F, Dhar DK, Webster GJ, Dooley JS, et al. Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer. J Clin Exp Hepatol 2011;1:6-12.
13. Leelawat K, Sakhinabut S, Narong S, Wannaprasert J. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol 2009;9:30.
14. Loosen SH, Roderburg C, Kauertz KL, Pombeiro I, Leyh C, Benz F, et al. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. J Hepatol 2017;67:749-57.
15. Macias RI, Kornek M, Rodrigues PM, Paiva NA, Castro RE, Urban S, et al. Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int 2019;39 Suppl 1:108-22.
16. Grunnet M, Mau-Sørensen M. Serum tumor markers in bile duct cancer: a review. Biomarkers 2014;19:437-43.
17. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
18. Kim JY, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-6.
19. Distler M, Pilarsky E, Kersting S, Grützmann R, Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas: a retrospective tumor marker prognostic study. Int J Surg 2013;11:1067-72.
20. Duraker N, Hot S, Polat Y, Höbek A, Gengler N, Urban N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007;95:142-7.
21. Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, et al.
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-22.

22. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-70.

23. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012;76:138-43.

24. Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, Bijedic N, Bjelogrlic I, Gogov B, et al. Cancer antigens (CEA and CA 19-9) as markers of advanced stage of colorectal carcinoma. Med Arch 2013;67:397-401.

25. Xing H, Wang J, Wang Y, Tong M, Hu H, Huang C, et al. Diagnostic value of CA 19-9 and carcinoembryonic antigen for pancreatic cancer: a meta-analysis. Gastroenterol Res Pract 2018:2018:8704751.

26. Jeong Y, Kim JH, Chae HD, Park SJ, Bae JS, Joo I, et al. Deep learning-based decision support system for the diagnosis of neoplastic gallbladder polyps on ultrasonography: preliminary results. Sci Rep 2020:10:7700.

27. Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg 2007;11:671-81.

28. Byun Y, Choi YJ, Kang JS, Han Y, Kim H, Kwon W, et al. Early outcomes of robotic extended cholecystectomy for the treatment of gallbladder cancer. J Hepatobiliary Pancreat Sci 2020;27:324-30.

29. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006;118:1591-602.

30. Pandey A, Stawiski EW, Durinck S, Gowda H, Goldstein LD, Barbhuiya MA, et al. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate. Nat Commun 2020;11:4225.